The National Comprehensive Cancer Network for immunotherapy recommends the detection of programmed death-ligand 1 (PD-L1) as the only prognostic biomarker for the development of effective therapies against metastatic NSCLC.7 The implementation of precision medicine, driven by a deeper understanding of the genomic alterations leading to the proliferation of cancer cells, has significantly transformed the therapeutic landscape for NSCLC.8 This includes the use of PDL-1 immune checkpoint inhibitors, viz. The gene discussed is CD274; the disease is cancer.